{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:57:38Z","timestamp":1781636258169,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"FCT","award":["UIDB\/04565\/2020 (DOI:10.54499\/UIDB\/04565\/2020) and UIDP\/04565\/2020 (DOI:10.54499\/UIDP\/04565\/2020) of the Research Unit Institute for Bioengineering and Biosciences (iBB); the project LA\/P\/0140\/2020 (DOI:10.54499\/LA\/P\/0140\/2020) of the Associate Laboratory Institute for Health and Bioeconomy (i4HB)"],"award-info":[{"award-number":["UIDB\/04565\/2020 (DOI:10.54499\/UIDB\/04565\/2020) and UIDP\/04565\/2020 (DOI:10.54499\/UIDP\/04565\/2020) of the Research Unit Institute for Bioengineering and Biosciences (iBB); the project LA\/P\/0140\/2020 (DOI:10.54499\/LA\/P\/0140\/2020) of the Associate Laboratory Institute for Health and Bioeconomy (i4HB)"]}]},{"name":"FCT","award":["UIDB\/04565\/2020 (DOI:10.54499\/UIDB\/04565\/2020) and UIDP\/04565\/2020 (DOI:10.54499\/UIDP\/04565\/2020) of the Research Unit Institute for Bioengineering and Biosciences (iBB); the project LA\/P\/0140\/2020 (DOI:10.54499\/LA\/P\/0140\/2020) of the Associate Laboratory Institute for Health and Bioeconomy (i4HB)"],"award-info":[{"award-number":["UIDB\/04565\/2020 (DOI:10.54499\/UIDB\/04565\/2020) and UIDP\/04565\/2020 (DOI:10.54499\/UIDP\/04565\/2020) of the Research Unit Institute for Bioengineering and Biosciences (iBB); the project LA\/P\/0140\/2020 (DOI:10.54499\/LA\/P\/0140\/2020) of the Associate Laboratory Institute for Health and Bioeconomy (i4HB)"]}]},{"name":"FCT","award":["UIDB\/04565\/2020 (DOI:10.54499\/UIDB\/04565\/2020) and UIDP\/04565\/2020 (DOI:10.54499\/UIDP\/04565\/2020) of the Research Unit Institute for Bioengineering and Biosciences (iBB); the project LA\/P\/0140\/2020 (DOI:10.54499\/LA\/P\/0140\/2020) of the Associate Laboratory Institute for Health and Bioeconomy (i4HB)"],"award-info":[{"award-number":["UIDB\/04565\/2020 (DOI:10.54499\/UIDB\/04565\/2020) and UIDP\/04565\/2020 (DOI:10.54499\/UIDP\/04565\/2020) of the Research Unit Institute for Bioengineering and Biosciences (iBB); the project LA\/P\/0140\/2020 (DOI:10.54499\/LA\/P\/0140\/2020) of the Associate Laboratory Institute for Health and Bioeconomy (i4HB)"]}]},{"name":"FCT","award":["UIDB\/04565\/2020 (DOI:10.54499\/UIDB\/04565\/2020) and UIDP\/04565\/2020 (DOI:10.54499\/UIDP\/04565\/2020) of the Research Unit Institute for Bioengineering and Biosciences (iBB); the project LA\/P\/0140\/2020 (DOI:10.54499\/LA\/P\/0140\/2020) of the Associate Laboratory Institute for Health and Bioeconomy (i4HB)"],"award-info":[{"award-number":["UIDB\/04565\/2020 (DOI:10.54499\/UIDB\/04565\/2020) and UIDP\/04565\/2020 (DOI:10.54499\/UIDP\/04565\/2020) of the Research Unit Institute for Bioengineering and Biosciences (iBB); the project LA\/P\/0140\/2020 (DOI:10.54499\/LA\/P\/0140\/2020) of the Associate Laboratory Institute for Health and Bioeconomy (i4HB)"]}]},{"name":"FCT","award":["UIDB\/04565\/2020 (DOI:10.54499\/UIDB\/04565\/2020) and UIDP\/04565\/2020 (DOI:10.54499\/UIDP\/04565\/2020) of the Research Unit Institute for Bioengineering and Biosciences (iBB); the project LA\/P\/0140\/2020 (DOI:10.54499\/LA\/P\/0140\/2020) of the Associate Laboratory Institute for Health and Bioeconomy (i4HB)"],"award-info":[{"award-number":["UIDB\/04565\/2020 (DOI:10.54499\/UIDB\/04565\/2020) and UIDP\/04565\/2020 (DOI:10.54499\/UIDP\/04565\/2020) of the Research Unit Institute for Bioengineering and Biosciences (iBB); the project LA\/P\/0140\/2020 (DOI:10.54499\/LA\/P\/0140\/2020) of the Associate Laboratory Institute for Health and Bioeconomy (i4HB)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Umbilical cord blood (CB)-derived natural killer (NK(CB)) cells are a promising immunotherapeutic modality due to their cytotoxicity, allogeneic compatibility, and reduced immunogenicity relative to peripheral blood NK cells (NK(PB)). Although several commercial culture media have been optimized for NK(PB) expansion, their suitability for NK(CB) cells remains insufficiently characterized. This study compares the expansion efficiency, phenotypic shifts, functional activation, and cost-effectiveness of NK(CB) cells expanded ex vivo under feeder-free static culture conditions with IL-2-supplemented culture media. CB-derived CD56\u207a cells isolated by magnetic-activated cell sorting were cultured in six candidate culture media, after which CTS\u2122 NK-Xpander\u2122 (NKX) and NK MACS\n                    <jats:sup>\u00ae<\/jats:sup>\n                    (NKM) with 1% (NKM1) or 2% (NKM2) supplement were selected for further evaluation. NKX achieved the highest average fold expansion (18.8\u2009\u00b1\u20097.0), followed by NKM2 (16.8\u2009\u00b1\u20097.3) and NKM1 (14.3\u2009\u00b1\u20093.5). All conditions increased cytotoxicity and CD107a degranulation, with NKX consistently yielding stronger functional responses. Phenotypic analysis revealed a shift toward a CD56\n                    <jats:sup>bright<\/jats:sup>\n                    CD16\u207b profile, particularly in NKM cultures, accompanied by cytokine-associated CD16 downregulation. Cost analysis identified NKX and NKM1 as the most cost-efficient conditions, whereas NKM2 doubled manufacturing costs due to higher supplement requirements. In conclusion, NKX and NKM media effectively support feeder-free ex vivo expansion of NK(CB) cells with high viability and robust functional activation. Phenotypic changes, donor-dependent variability, and CD16 downregulation should be considered when designing clinically translatable manufacturing strategies. These findings are essential to enhance scalability, reduce manufacturing costs, and advance NK(CB) cells as an accessible and effective immunotherapy, facilitating their integration into clinical-grade manufacturing and scalable bioprocessing pipelines.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-41101-5","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:20:48Z","timestamp":1771921248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feeder-free ex vivo expansion of cord blood-derived natural killer cells for enhanced proliferation and functional maturation"],"prefix":"10.1038","volume":"16","author":[{"given":"Isabel","family":"Doutor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Filipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Lilaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Fonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fernandes-Platzgummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"41101_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki, N., Jain, A. & Campana, D. NK cells for cancer immunotherapy. Nat. Rev. Drug Discov. 19, 200\u2013218. https:\/\/doi.org\/10.1038\/s41573-019-0052-1 (2020).","journal-title":"Nat. Rev. Drug Discov"},{"key":"41101_CR2","doi-asserted-by":"publisher","unstructured":"Mehta, R. S., Shpall, E. J. & Rezvani, K. Cord blood as a source of natural killer cells. Front. Med. (Lausanne). 2. https:\/\/doi.org\/10.3389\/fmed.2015.00093 (2015).","DOI":"10.3389\/fmed.2015.00093"},{"key":"41101_CR3","doi-asserted-by":"publisher","unstructured":"Sarvaria, A., Jawdat, D., Madrigal, J. A. & Saudemont, A. Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications. Front. Immunol. 8 https:\/\/doi.org\/10.3389\/fimmu.2017.00329 (2017).","DOI":"10.3389\/fimmu.2017.00329"},{"key":"41101_CR4","doi-asserted-by":"publisher","unstructured":"Wang, J. & Metheny, L. Umbilical cord blood derived cellular therapy: advances in clinical development. Front. Oncol. 13 https:\/\/doi.org\/10.3389\/FONC.2023.1167266 (2023).","DOI":"10.3389\/FONC.2023.1167266"},{"key":"41101_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1365-2141.2009.07768.x","volume":"147","author":"MR Verneris","year":"2009","unstructured":"Verneris, M. R. & Miller, J. S. The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. Br. J. Haematol. 147, 185\u2013191. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07768.x (2009).","journal-title":"Br. J. Haematol."},{"key":"41101_CR6","doi-asserted-by":"publisher","unstructured":"Herrera, L. et al. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells. Sci. Rep. 9 https:\/\/doi.org\/10.1038\/s41598-019-55239-y (2019).","DOI":"10.1038\/s41598-019-55239-y"},{"key":"41101_CR7","doi-asserted-by":"publisher","unstructured":"Sanchez-Petitto, G. et al. Umbilical cord blood transplantation: Connecting its origin to its future. Stem Cells Transl. Med. 1\u201317. https:\/\/doi.org\/10.1093\/stcltm\/szac086\/7035391 (2023).","DOI":"10.1093\/stcltm\/szac086\/7035391"},{"key":"41101_CR8","doi-asserted-by":"publisher","unstructured":"Zhao, X., Cai, L., Hu, Y. & Wang, H. Cord-blood natural killer cell-based immunotherapy for cancer. Front. Immunol. 11 https:\/\/doi.org\/10.3389\/fimmu.2020.584099 (2020).","DOI":"10.3389\/fimmu.2020.584099"},{"key":"41101_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/10_2019_118","volume":"171","author":"M de Almeida Fuzeta","year":"2020","unstructured":"de Almeida Fuzeta, M. et al. Addressing the manufacturing challenges of cell-based therapies. Adv. Biochem. Eng. Biotechnol. 171, 225\u2013278. https:\/\/doi.org\/10.1007\/10_2019_118 (2020).","journal-title":"Adv. Biochem. Eng. Biotechnol."},{"key":"41101_CR10","doi-asserted-by":"publisher","unstructured":"Spanholtz, J. et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One. 6 https:\/\/doi.org\/10.1371\/journal.pone.0020740 (2011).","DOI":"10.1371\/journal.pone.0020740"},{"key":"41101_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jcyt.2015.09.011","volume":"18","author":"J Masuyama","year":"2016","unstructured":"Masuyama, J., Murakami, T., Iwamoto, S. & Fujita, S. Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies. Cytotherapy 18, 80\u201390. https:\/\/doi.org\/10.1016\/j.jcyt.2015.09.011 (2016).","journal-title":"Cytotherapy"},{"key":"41101_CR12","doi-asserted-by":"publisher","first-page":"10961","DOI":"10.1073\/PNAS.1005641107","volume":"107","author":"M Cella","year":"2010","unstructured":"Cella, M., Otero, K. & Colonna, M. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1\u03b2 reveals intrinsic functional plasticity. Proc. Natl. Acad. Sci. U S A. 107, 10961\u201310966. https:\/\/doi.org\/10.1073\/PNAS.1005641107 (2010).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"41101_CR13","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.jcyt.2015.07.011","volume":"17","author":"A P\u00e9rez-Mart\u00ednez","year":"2015","unstructured":"P\u00e9rez-Mart\u00ednez, A. et al. A phase I\/II trial of interleukin-15-stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. Cytotherapy 17, 1594\u20131603. https:\/\/doi.org\/10.1016\/j.jcyt.2015.07.011 (2015).","journal-title":"Cytotherapy"},{"key":"41101_CR14","doi-asserted-by":"publisher","unstructured":"Lee, H. R. et al. Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody. Sci. Rep. 7 https:\/\/doi.org\/10.1038\/S41598-017-09259-1 (2017).","DOI":"10.1038\/S41598-017-09259-1"},{"key":"41101_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/CEI.12034","volume":"172","author":"X Wang","year":"2013","unstructured":"Wang, X. et al. Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation. Clin. Exp. Immunol. 172, 104\u2013112. https:\/\/doi.org\/10.1111\/CEI.12034 (2013).","journal-title":"Clin. Exp. Immunol."},{"key":"41101_CR16","doi-asserted-by":"publisher","first-page":"257309","DOI":"10.3389\/FIMMU.2017.00458\/XML\/NLM","volume":"8","author":"M Granzin","year":"2017","unstructured":"Granzin, M. et al. Shaping of natural killer cell antitumor activity by ex vivo cultivation. Front. Immunol. 8, 257309. https:\/\/doi.org\/10.3389\/FIMMU.2017.00458\/XML\/NLM (2017).","journal-title":"Front. Immunol."},{"key":"41101_CR17","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/HUM.2017.157","volume":"28","author":"S Kl\u00f6\u00df","year":"2017","unstructured":"Kl\u00f6\u00df, S. et al. Optimization of human NK cell manufacturing: fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of anti-CD123-CAR-expressing effector cells. Hum. Gene Ther. 28, 897\u2013913. https:\/\/doi.org\/10.1089\/HUM.2017.157 (2017).","journal-title":"Hum. Gene Ther."},{"key":"41101_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13030577","volume":"13","author":"A Fern\u00e1ndez","year":"2021","unstructured":"Fern\u00e1ndez, A. et al. Optimizing the procedure to manufacture clinical\u2010grade NK cells for adoptive immunotherapy. Cancers (Basel). 13, 1\u201324. https:\/\/doi.org\/10.3390\/cancers13030577 (2021).","journal-title":"Cancers (Basel)"},{"key":"41101_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02785-8","author":"D Marin","year":"2024","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19\u2009+\u2009B cell tumors: a phase 1\/2 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-023-02785-8 (2024).","journal-title":"Nat. Med."},{"key":"41101_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01207-0","author":"L Peng","year":"2024","unstructured":"Peng, L. et al. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell. Mol. Immunol. https:\/\/doi.org\/10.1038\/s41423-024-01207-0 (2024).","journal-title":"Cell. Mol. Immunol."},{"key":"41101_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12032-024-02362-0","volume":"41","author":"SH Hassan","year":"2024","unstructured":"Hassan, S. H. et al. A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases. Med. Oncol. 41, 127. https:\/\/doi.org\/10.1007\/s12032-024-02362-0 (2024).","journal-title":"Med. Oncol."},{"key":"41101_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1089\/HUM.2018.247","volume":"30","author":"S Kloess","year":"2019","unstructured":"Kloess, S. et al. Preclinical assessment of suitable natural killer cell sources for chimeric antigen receptor natural killer-based off-the-shelf acute myeloid leukemia immunotherapies. Hum. Gene Ther. 30, 381\u2013401. https:\/\/doi.org\/10.1089\/HUM.2018.247 (2019).","journal-title":"Hum. Gene Ther."},{"key":"41101_CR23","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller, J. S. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051\u20133057. https:\/\/doi.org\/10.1182\/blood-2004-07-2974 (2005).","journal-title":"Blood"},{"key":"41101_CR24","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.exphem.2011.06.003","volume":"39","author":"G Suck","year":"2011","unstructured":"Suck, G. et al. Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies. Exp. Hematol. 39, 904\u2013914. https:\/\/doi.org\/10.1016\/j.exphem.2011.06.003 (2011).","journal-title":"Exp. Hematol."},{"key":"41101_CR25","doi-asserted-by":"publisher","unstructured":"Huang, R. S., Lai, M. C., Shih, H. A. & Lin, S. A robust platform for expansion and genome editing of primary human natural killer cells. JEM. 218 https:\/\/doi.org\/10.1084\/JEM.20201529 (2021).","DOI":"10.1084\/JEM.20201529"},{"key":"41101_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-1-4939-8885-3_7","volume":"1884","author":"S Lorenzo-Herrero","year":"2019","unstructured":"Lorenzo-Herrero, S., Sordo-Bahamonde, C., Gonzalez, S. & L\u00f3pez-Soto, A. CD107a degranulation assay to evaluate immune cell antitumor activity. Methods Mol. 1884, 119\u2013130. https:\/\/doi.org\/10.1007\/978-1-4939-8885-3_7 (2019).","journal-title":"Methods Mol."},{"key":"41101_CR27","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand, A. et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell. Metab. 24, 657\u2013671. https:\/\/doi.org\/10.1016\/j.cmet.2016.08.011 (2016).","journal-title":"Cell. Metab."},{"key":"41101_CR28","doi-asserted-by":"publisher","unstructured":"Shah, N. et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0076781 (2013).","DOI":"10.1371\/JOURNAL.PONE.0076781"},{"key":"41101_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.humimm.2011.12.015","volume":"73","author":"M Luevano","year":"2012","unstructured":"Luevano, M. et al. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum. Immunol. 73, 248\u2013257. https:\/\/doi.org\/10.1016\/j.humimm.2011.12.015 (2012).","journal-title":"Hum. Immunol."},{"key":"41101_CR30","doi-asserted-by":"publisher","unstructured":"Fumarola, S. et al. Predictors of cord blood unit cell content in a volume unrestricted large series collections: a chance for a fast and cheap multiparameter selection model. Stem Cell. Res. Ther. 13 https:\/\/doi.org\/10.1186\/S13287-022-02915-Y (2022).","DOI":"10.1186\/S13287-022-02915-Y"},{"key":"41101_CR31","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/BLOODADVANCES.2017008631","volume":"1","author":"L Maggs","year":"2017","unstructured":"Maggs, L. et al. The number of CD56dim NK cells in the graft has a major impact on risk of disease relapse following allo-HSCT. Blood Adv. 1, 1589\u20131597. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2017008631 (2017).","journal-title":"Blood Adv."},{"key":"41101_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.actbio.2020.05.004","volume":"112","author":"K Bacon","year":"2020","unstructured":"Bacon, K. et al. Past, present, and future of affinity-based cell separation technologies. Acta Biomater. 112, 29\u201351. https:\/\/doi.org\/10.1016\/j.actbio.2020.05.004 (2020).","journal-title":"Acta Biomater."},{"key":"41101_CR33","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1007\/S10238-022-00974-2","volume":"23","author":"TV Shman","year":"2023","unstructured":"Shman, T. V. et al. Phenotypic and functional characterisation of locally produced natural killer cells ex vivo expanded with the K562-41BBL-mbIL21 cell line. Clin. Exp. Med. 23, 2551\u20132560. https:\/\/doi.org\/10.1007\/S10238-022-00974-2 (2023).","journal-title":"Clin. Exp. Med."},{"key":"41101_CR34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.reth.2022.07.001","volume":"21","author":"T Nakazawa","year":"2022","unstructured":"Nakazawa, T. et al. Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors. Regen. Ther. 21, 185\u2013191. https:\/\/doi.org\/10.1016\/j.reth.2022.07.001 (2022).","journal-title":"Regen. Ther."},{"key":"41101_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2005.04.022","volume":"303","author":"A \u00d8ren","year":"2005","unstructured":"\u00d8ren, A., Huseb\u00f8, C., Iversen, A. C. & Austgulen, R. A comparative study of immunomagnetic methods used for separation of human natural killer cells from peripheral blood. J. Immunol. Methods. 303, 1\u201310. https:\/\/doi.org\/10.1016\/j.jim.2005.04.022 (2005).","journal-title":"J. Immunol. Methods"},{"key":"41101_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/BMT.2009.89","volume":"45","author":"A Willasch","year":"2010","unstructured":"Willasch, A. et al. Enrichment of cell subpopulations applying automated MACS technique: Purity, recovery and applicability for PCR-based chimerism analysis. Bone Marrow Transpl. 45, 181\u2013189. https:\/\/doi.org\/10.1038\/BMT.2009.89 (2010).","journal-title":"Bone Marrow Transpl."},{"key":"41101_CR37","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3892\/ETM.2017.4189","volume":"13","author":"G Wang","year":"2017","unstructured":"Wang, G. et al. Comparison of the purity and vitality of natural killer cells with different isolation kits. Exp. Ther. Med. 13, 1875\u20131883. https:\/\/doi.org\/10.3892\/ETM.2017.4189 (2017).","journal-title":"Exp. Ther. Med."},{"key":"41101_CR38","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1089\/HGTB.2019.039","volume":"30","author":"O Oberschmidt","year":"2019","unstructured":"Oberschmidt, O. et al. Development of automated separation, expansion, and quality control protocols for clinical-scale manufacturing of primary human NK cells and alpharetroviral chimeric antigen receptor engineering. Hum. Gene Ther. Methods. 30, 102\u2013120. https:\/\/doi.org\/10.1089\/HGTB.2019.039 (2019).","journal-title":"Hum. Gene Ther. Methods"},{"key":"41101_CR39","doi-asserted-by":"publisher","unstructured":"Jung, D. et al. Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions. J. Exp. Clin. Cancer Res. 40 https:\/\/doi.org\/10.1186\/s13046-021-02089-0 (2021).","DOI":"10.1186\/s13046-021-02089-0"},{"key":"41101_CR40","doi-asserted-by":"publisher","unstructured":"Ma, M., Badeti, S., Kim, J. K. & Liu, D. Natural killer (NK) and CAR-NK cell expansion method using membrane bound-IL-21-modified B cell line. JoVE. 2022. https:\/\/doi.org\/10.3791\/62336 (2022).","DOI":"10.3791\/62336"},{"key":"41101_CR41","doi-asserted-by":"publisher","unstructured":"Sahin, U. & Beksac, M. Natural killer cell-mediated cellular therapy of hematological malignancies. Clin. Hematol. Int. 1 https:\/\/doi.org\/10.2991\/CHI.D.190623.001 (2019).","DOI":"10.2991\/CHI.D.190623.001"},{"key":"41101_CR42","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/J.1537-2995.2012.03724.X","volume":"53","author":"SA Koepsell","year":"2013","unstructured":"Koepsell, S. A., Miller, J. S. & McKenna, D. H. Natural killer cells: A review of manufacturing and clinical utility. Transfus. (Paris). 53, 404\u2013410. https:\/\/doi.org\/10.1111\/J.1537-2995.2012.03724.X (2013).","journal-title":"Transfus. (Paris)"},{"key":"41101_CR43","doi-asserted-by":"publisher","unstructured":"Kim, M. et al. Multi-cellular natural killer (NK) cell clusters enhance NK cell activation through localizing IL-2 within the cluster. Sci. Rep. 7 https:\/\/doi.org\/10.1038\/SREP40623 (2017).","DOI":"10.1038\/SREP40623"},{"key":"41101_CR44","doi-asserted-by":"publisher","unstructured":"Wang, X. et al. Scalable process development of NK and CAR-NK expansion in a closed bioreactor. Front. Immunol. 15 https:\/\/doi.org\/10.3389\/fimmu.2024.1412378 (2024).","DOI":"10.3389\/fimmu.2024.1412378"},{"key":"41101_CR45","doi-asserted-by":"publisher","unstructured":"Branco, A. et al. Tailored cytokine optimization for ex vivo culture platforms targeting the expansion of human hematopoietic stem\/progenitor cells. Front. Bioeng. Biotechnol. 8 https:\/\/doi.org\/10.3389\/FBIOE.2020.573282 (2020).","DOI":"10.3389\/FBIOE.2020.573282"},{"key":"41101_CR46","doi-asserted-by":"publisher","unstructured":"Pittari, G. et al. Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies. Front. Immunol. 6 https:\/\/doi.org\/10.3389\/fimmu.2015.00230 (2015).","DOI":"10.3389\/fimmu.2015.00230"},{"key":"41101_CR47","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/imcb.12658","volume":"101","author":"SZF Kiaei","year":"2023","unstructured":"Kiaei, S. Z. F. et al. Advances in natural killer cell therapies for breast cancer. Immunol. Cell. Biol. 101, 705\u2013726. https:\/\/doi.org\/10.1111\/imcb.12658 (2023).","journal-title":"Immunol. Cell. Biol."},{"key":"41101_CR48","doi-asserted-by":"publisher","unstructured":"Veluchamy, J. P. et al. Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function. Sci. Rep. 7 https:\/\/doi.org\/10.1038\/SREP43873 (2017).","DOI":"10.1038\/SREP43873"},{"key":"41101_CR49","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1182\/blood-2012-04","volume":"121","author":"R Romee","year":"2013","unstructured":"Romee, R. et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 121, 3599\u20133608. https:\/\/doi.org\/10.1182\/blood-2012-04 (2013).","journal-title":"Blood"},{"key":"41101_CR50","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.tibtech.2023.03.018","volume":"41","author":"P Motallebnejad","year":"2023","unstructured":"Motallebnejad, P. et al. Process engineering of natural killer cell-based immunotherapy. Trends Biotechnol. 41, 1314\u20131326. https:\/\/doi.org\/10.1016\/j.tibtech.2023.03.018 (2023).","journal-title":"Trends Biotechnol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41101-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41101-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41101-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:46:05Z","timestamp":1781635565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41101-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["41101"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-41101-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Umbilical cord blood units were obtained from healthy donors at Hospital S\u00e3o Francisco Xavier, Centro Hospitalar de Lisboa Ocidental (Lisbon, Portugal), upon informed consent, according to Directive 2004\/23\/EC of the European Parliament and of the Council of 31 March 2004 regarding standards of quality and safety for the donation, procurement, testing, processing, preservation, storage, and distribution of human tissues and cells (Portuguese Law 22\/2007, 29 June). The study was approved by the Ethics Committee of Centro Hospitalar de Lisboa Ocidental (CHLO). All methods were performed in accordance with the relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"10417"}}